[{"orgOrder":0,"company":"Baylor College of Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Targeted Drug Prevents Heart Failure in Mouse Models","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"MCB-613","moa":"Steroid receptor","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Baylor College of Medicine","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Baylor College of Medicine \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Baylor Col.."},{"orgOrder":0,"company":"Baylor College of Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Baylor Recruiting Melas Syndrome Patients for Phase 1 Clinical Trial","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Citrulline","moa":"Atherogenic","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Baylor College of Medicine","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Baylor College of Medicine \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Baylor Col.."},{"orgOrder":0,"company":"Baylor College of Medicine","sponsor":"Effector Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Baylor College of Medicine to Present eFFECTOR Therapeutics-Supported Research at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Zotatifin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Baylor College of Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Baylor College of Medicine \/ Baylor College of Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Baylor Col.."},{"orgOrder":0,"company":"Baylor College of Medicine","sponsor":"Effector Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Baylor College of Medicine Presents eFFECTOR Therapeutics-Backed Preclinical Data Supporting Development of Zotatifin in Triple-Negative Breast Cancer at 2021 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Zotatifin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Baylor College of Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Baylor College of Medicine \/ Baylor College of Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Baylor Col.."},{"orgOrder":0,"company":"Baylor College of Medicine","sponsor":"BridgeBio Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BridgeBio Pharma Announces Academic Collaboration with Baylor College of Medicine to Advance Potential Therapies to Treat Genetic Diseases","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"July 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Baylor College of Medicine","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Baylor College of Medicine \/ Baylor College of Medicine","highestDevelopmentStatusID":"2","companyTruncated":"Baylor Col.."},{"orgOrder":0,"company":"Baylor College of Medicine","sponsor":"Tessa Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tessa Therapeutics, Baylor College of Medicine Execute Agreement For Global Commercial Rights to \u2018Off-the-Shelf\u2019 CAR-T Platform","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Agreement","leadProduct":"CD30.CAR-EBVST Cells","moa":"CD30","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Baylor College of Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Baylor College of Medicine \/ Baylor College of Medicine","highestDevelopmentStatusID":"6","companyTruncated":"Baylor Col.."},{"orgOrder":0,"company":"Baylor College of Medicine","sponsor":"Immunai","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunai and Baylor College of Medicine Provide Updated Interim Phase 1 Results for anti-GD2 CAR NKT-Cell Therapy in Relapsed\/Refractory Neuroblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Baylor College of Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Baylor College of Medicine \/ Baylor College of Medicine","highestDevelopmentStatusID":"6","companyTruncated":"Baylor Col.."}]

Find Clinical Drug Pipeline Developments & Deals by Baylor College of Medicine

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Boulder Peptide 2024
                          Not Confirmed
                          Boulder Peptide 2024
                          Not Confirmed

                          Details : Anti-GD2 CAR NKT-Cell Therapy targeting BTG1 which is identified as a novel molecular target that can be used to enhance the potency of natural killer T (NKT)- and T cell-based cancer immunotherapy. It is...

                          Product Name : Undisclosed

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Not Applicable

                          May 15, 2023

                          Lead Product(s) : GINAKIT Cell Therapy,Cyclophosphamide,Fludarabine Phosphate

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Recipient : Immunai

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          Boulder Peptide 2024
                          Not Confirmed
                          Boulder Peptide 2024
                          Not Confirmed

                          Details : TT11X (CD30.CAR-EBVST cells) utilizes CD30.CAR-modified Allogeneic Epstein-Barr Virus Specific T-Cell (EBVST) to target relapsed or refractory CD30-positive lymphomas.

                          Product Name : TT11X

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          November 07, 2022

                          Lead Product(s) : CD30.CAR-EBVST Cells

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Recipient : Tessa Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          03

                          Boulder Peptide 2024
                          Not Confirmed
                          Boulder Peptide 2024
                          Not Confirmed

                          Details : Through this collaboration, BridgeBio will work with Baylor College of Medicine to identify and translate promising innovations into potential therapies for patients with genetically driven diseases.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          July 21, 2022

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Discovery

                          Recipient : BridgeBio Pharma

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          04

                          Boulder Peptide 2024
                          Not Confirmed
                          Boulder Peptide 2024
                          Not Confirmed

                          Details : Zotatifin is a potent and sequence-selective inhibitor of eukaryotic translation initiation factor 4A (eIF4A) mediated translation used in solid tumor indications, including triple negative breast cancer.

                          Product Name : eFT226

                          Product Type : Small molecule

                          Upfront Cash : Not Applicable

                          October 07, 2021

                          Lead Product(s) : Zotatifin

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Recipient : Effector Therapeutics

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          05

                          Boulder Peptide 2024
                          Not Confirmed
                          Boulder Peptide 2024
                          Not Confirmed

                          Details : Zotatifin, is a small molecule inhibitor of eIF4A. eIF4A is a helicase responsible for unwinding complex secondary structures in “onco” mRNAs and enables select tumor cells to overproduce proteins ass...

                          Product Name : eFT226

                          Product Type : Small molecule

                          Upfront Cash : Not Applicable

                          September 30, 2021

                          Lead Product(s) : Zotatifin

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Recipient : Effector Therapeutics

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          06

                          Boulder Peptide 2024
                          Not Confirmed
                          Boulder Peptide 2024
                          Not Confirmed

                          Details : The Phase 1 safety study will test the safest maximum dose of L-citrulline for patients with MELAS. Once established, this dose will be used in a future clinical trial that will test the efficacy of L-cit...

                          Product Name : Undisclosed

                          Product Type : Small molecule

                          Upfront Cash : Not Applicable

                          April 29, 2021

                          Lead Product(s) : Citrulline

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase I

                          Partner/Sponsor/Collaborator : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          07

                          Boulder Peptide 2024
                          Not Confirmed
                          Boulder Peptide 2024
                          Not Confirmed

                          Details : The researchers used an experimental drug called MCB-613 within hours after heart attack in mouse models. The drug prompted the production of proteins called steroid receptor coactivators (SRCs).

                          Product Name : MCB-613

                          Product Type : Small molecule

                          Upfront Cash : Not Applicable

                          March 22, 2021

                          Lead Product(s) : MCB-613

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Preclinical

                          Partner/Sponsor/Collaborator : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank